Diabetic retinopathy is a complication of diabetes that affects the eye. High blood sugar damages the tiny blood vessels in the retina, causing them to leak fluid and blood. If left untreated, diabetic retinopathy can worsen and lead to serious vision problems, including diabetic macular edema (DME). Several FDA-approved biologics, including Roche's Susvimo, Vabysmo, and Lucentis, as well as Regeneron Pharma's Eylea, help manage diabetic retinopathy by targeting abnormal blood vessel growth and leakage.
The company we are profiling today is Kodiak Sciences Inc. (KOD), which is developing a drug using its ABC Platform, designed to extend ocular half-life compared to existing intravitreal biologics, potentially reducing treatment frequency in diabetic retinopathy patients.
For comments and feedback: editorial@rttnews.com